NCT05486169 (SLEEFLUX) is a NA clinical trial of Sleeve Gastrectomy in Gastroesophageal Reflux, sponsored by University of Warmia and Mazury in Olsztyn.

Who is sponsoring NCT05486169?

NCT05486169 is sponsored by University of Warmia and Mazury in Olsztyn.

What drugs are being tested in NCT05486169?

Interventions in NCT05486169: Sleeve Gastrectomy.

What condition does NCT05486169 study?

NCT05486169 studies Gastroesophageal Reflux, Obesity.

Is NCT05486169 still recruiting?

NCT05486169 is currently completed. Last updated 3 January 2024.

Last reviewed 2024-01-03 · How we verify

NCT05486169: SLEEFLUX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy

Completed NA Last updated 3 January 2024

What this trial tests

NA trial testing Sleeve Gastrectomy in Gastroesophageal Reflux in 50 participants. Completed in 31 August 2023.

Timeline

1 September 2022

Primary endpoint
31 July 2023

31 August 2023

Quick facts

Lead sponsor	University of Warmia and Mazury in Olsztyn
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	50
Start date	1 September 2022
Primary completion	31 July 2023
Estimated completion	31 August 2023
Sites	1 location across Poland

Drugs / interventions tested

Sleeve Gastrectomy

Conditions studied

Gastroesophageal Reflux — all drugs for Gastroesophageal Reflux →
Obesity — all drugs for Obesity →

Sponsor

University of Warmia and Mazury in Olsztyn

Who can join

18 and older, any sex, with Gastroesophageal Reflux or Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The planned research is to analyze the occurrence of gastroesophageal reflux disease (GERD) before and after sleeve gastrectomy (SG). The study includes patients with BMI above 40 kg / m2 without symptoms of GERD before surgery and any pathological changes in gastroscopy. The day before the surgery, patients will be tested with impedance pH measurement. Thereafter, patients will undergo SG according to standard technique. As part of the follow-up 6 months after the surgery, the pH-measurement test with impedance again will be performed again for evaluation of the occurrence of GERD after surgery. It was planned to include 50 people in the study. The main aim of the study is to assess the frequency and quality of GERD in patients after SG.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The real occurrence of gastroesophageal reflux disease after sleeve gastrectomy - a prospective pH-monitoring study.
Dowgiałło-Gornowicz N, Lech P. · · 2024 · cited 3× · PMID 38973794 · DOI 10.5114/wiitm.2024.138521
Systematic mapping of registered interventional studies addressing the top 10 research priorities in Barrett's oesophagus and gastro-oesophageal reflux disease.
Gamakaranage C, Ratcliffe E, Britton J, Butler T, et al · · 2025 · PMID 40527525 · DOI 10.1136/bmjgast-2025-001738

Verify or expand the search:

Other trials of Sleeve Gastrectomy

Trials testing the same drug.

NCT07058155 — Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease · Phase 4 · recruiting
NCT07263269 — Comparing Dumping Symptoms and Quality of Life 6 Months After Sleeve Gastrectomy With or Without Transit Bipartition in · NA · active not recruiting
NCT05224791 — A Retrospective Multicenter Comparison of Laparoscopic and Robotic-Assisted Roux-en-Y Gastrectomy · unknown
NCT04079023 — Alcohol Metabolism After Sleeve Gastrectomy · completed
NCT03339791 — Sleeve Versus Bypass in Older Patients: a Randomized Controlled Trial · NA · completed

Other recruiting trials for Gastroesophageal Reflux

Currently open trials in the same condition.

NCT07291700 — Study on Hydrotalcite for Relief of Acid Symptoms Due to Acid Rebound After Stopping Long-Term PPI Therapy · recruiting
NCT06255886 — Treatment of Gastroesophageal Reflux Disease in Infants · Phase 4 · recruiting
NCT06534359 — Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia · NA · recruiting
NCT06687603 — Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms · NA · recruiting
NCT06339801 — Role of Mucosal Impedance Measurement for the Diagnosis of Gastroesophageal Reflux Disease · recruiting

Other University of Warmia and Mazury in Olsztyn trials

Trials by the same sponsor.

NCT07258732 — The Impact of Probiotics on Bariatric Treatment Outcomes · NA · active not recruiting
NCT06610253 — Evaluation of the Impact of the Consumption of Plant-derived Protein Supplements Compared to Animal-derived Proteins · NA · completed
NCT06081413 — Bariatric and Metabolic Surgery in Patients Over 65 Years of Age · completed
NCT07176299 — Unilateral Laparoscopic TAP Block vs. Local Infiltration in Post-Cholecystectomy Analgesia · NA · completed
NCT04845386 — : A Comparison of Neuromuscular Transmission in the Muscles During General Anesthesia · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05486169 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Warmia and Mazury in Olsztyn
Last refreshed: 3 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05486169.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing